Versantis has closed a series B financing round, and plans to use the funds to fuel the completion of ongoing Phase 1b studies with VS-01 and advance its clinical development up to clinical proof-of-efficacy (phase 2a) in 2 indications.
Tag: liver disease
Promethera Biosciences Presents Updated Phase 2a Results for World’s First Stem Cell Clinical Trial in ACLF at The International Liver Congress™/ EASL 2019
Promethera Biosciences’ Interim safety results and early efficacy signals with HepaStem bodewell for subsequent confirmatory trials in ACLF and provide valuableinsights for imminent start of clinical evaluation in NASH
FDA OK’s AkaRx’s liver drug
The U.S. Food and Drug Administration has approved AkaRx’s Doptelet (avatrombopag) tablets to treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. This is the first drug approved by the FDA for this use.
Albiero Pharma completes public offering, $69.9 million net
Boston-based Albireo Pharma, a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, has completed its public offering of 1,970,000 shares of its common stock at a price to the public of $33.00 per share.
Tiziana Life Sciences welcomes liver specialist to its Scientific Advisory Board
Tiziana Life Sciences, a clinical stage biotechnology company developing targeted drugs for cancer, autoimmune and inflammatory diseases, has appointed Dr. Arun Sanyal as a new member of its Scientific Advisory Board.
Novartis, Conatus in borad deal to make treatments for liver diseases
Novartis and Conatus Pharmaceuticals have signed a multipurpose deal which will help the two drug makers to make liver-disease treatment, emricasan.
FDA OK’s Cerenis’s CER-209 clinical trial for liver disease treatment
U.S. Food and Drug Administration (FDA) has given green light to Cerenis Therapeutics to proceed with CER-209 clinical trial.